Longeveron (LGVN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 May, 2026Executive summary
The annual meeting will be held virtually on July 1, 2026, with stockholders able to vote online or by proxy, enhancing accessibility and participation.
Stockholders will vote on director elections, amendments to the certificate of incorporation, incentive plan changes, auditor ratification, and potential adjournment.
Proxy materials are distributed primarily via internet, with paper copies available upon request, and voting is open to holders of record as of May 11, 2026.
Voting matters and shareholder proposals
Election of three Class II directors to serve until the 2029 annual meeting.
Approval to increase authorized Class A common stock to 175,000,000 shares.
Approval for a reverse stock split at a ratio between 1:2 and 1:20, at the Board's discretion.
Amendment to the 2021 Incentive Award Plan to add 5,000,000 shares.
Ratification of CBIZ CPAs P.C. as independent auditor for 2026.
Approval to adjourn the meeting if more time is needed to solicit votes for key proposals.
Board of directors and corporate governance
The Board is divided into three classes, with five current directors and three nominees for election.
Board committees include Audit, Compensation, Nominating and Corporate Governance, and Science and Strategy, each with defined charters.
Majority of the Board is independent; executive sessions are held without management.
Directors receive annual retainers, committee fees, and equity awards; temporary fee reductions were implemented and later restored.
Latest events from Longeveron
- Virtual meeting to vote on directors, capital changes, and auditor, with online proxy access.LGVN
Proxy filing20 May 2026 - Net loss narrowed to $4.7M in Q1 2026, but future operations require new funding and partnerships.LGVN
Q1 202619 May 2026 - Capital-light strategy and licensing focus position laromestrocel for major value inflection in 2026.LGVN
Investor presentation13 May 2026 - Annual meeting covers director elections, share structure changes, incentive plan, and auditor ratification.LGVN
Proxy filing5 May 2026 - HLHS Phase 2b data and PRV eligibility position laromestrocel for major value inflection.LGVN
Investor presentation4 May 2026 - Biotech registers resale of shares amid financial uncertainty and ongoing clinical development.LGVN
Registration filing10 Apr 2026 - Laromestrocel shows strong clinical progress and regulatory momentum across multiple indications.LGVN
Investor presentation1 Apr 2026 - Positive clinical progress in stem cell therapies for rare and aging-related diseases.LGVN
Investor presentation18 Mar 2026 - $15M financing extends runway as pivotal HLHS trial nears, despite 50% revenue drop and higher losses.LGVN
Q4 202517 Mar 2026